Alternative antimicrobial compounds could come from wastewater
Municipal wastewater may become a key ally in the fight against antibiotic-resistant disease-causing bacteria and fungi, a new study at Stellenbosch University (SU) found.

This is South African microbiologist, Dr Thando Ndlovu in his laboratory in the Department Microbiology, Stellenbosch University.
Stefan Els
"Certain bacteria in municipal wastewater produce antimicrobial compounds or biosurfactants that can help prevent the growth of antibiotic-resistant microorganisms which cause serious infections in humans," says Dr Thando Ndlovu a postdoctoral researcher in the Department of Microbiology at SU. Ndlovu recently obtained his doctorate in Microbiology at SU under the supervision of Prof Wesaal Khan from the same department.
He says the rapid increase in the emergence of antibiotic-resistant bacteria was a major reason behind his search for new antimicrobial compounds.
As part of his research, Ndlovu collected wastewater samples and also carried out molecular and microbiological tests in a laboratory on various biosurfactants-producing bacteria found in these samples. He isolated two bacterial strains whose biosurfactants proved effective against antibiotic-resistant disease-causing bacteria.
Biosurfactants are compounds produced naturally by bacteria, fungi or yeasts and they have been commercially utilised in shampoos, shower gels, and household cleaning products. They are also used in food, agriculture, cosmetic and medical industries as well as in environmental bioremediation to prevent the spread of spoilage and disease-causing bacteria.
"The biosurfactants produced by the two bacteria in my study prevented the growth of major disease-causing bacteria such as methicillin-resistant Staphylococcus aureus and gentamicin-resistant E. coli which can lead to life-threatening infections in humans," says Ndlovu.
"This finding is promising given worldwide reports on the number of deaths caused by antimicrobial resistant microorganisms that are becoming increasingly difficult to treat with current drugs."
"The discovery of novel antimicrobial compounds is a priority and biosurfactant compounds could be used to develop new antibiotics for treatment of various infections caused by antibiotic resistant bacteria and eventually replace ineffective antibiotics in future."
Ndlovu says his study showed that municipal wastewater is ideal for the isolation of diverse biosurfactant-producing bacteria that could be utilised in the production of such compounds for commercial use.
"While numerous studies have reported on the isolation of biosurfactant-producing bacteria from contaminated soil and terrestrial environments, the current study indicated that municipal wastewater could be exploited for the isolation of diverse biosurfactant-producing bacterial strains."
"Biosurfactant-producing bacteria thrive in polluted environments such as contaminated soil or water. These bacteria also have the ability to outcompete other bacteria in the same environment because the biosurfactant compounds help them to absorb nutrients and to protect them from toxic materials."
Ndlovu adds that biosurfactant compounds can be used to reduce the use of synthetic antimicrobial agents for various purposes such as cleaning and coating agents to prevent the build-up of disease-causing and spoilage bacteria.
As far as future research is concerned, Ndlovu says he is now focusing on the application of biosurfactant compounds with antimicrobial properties.
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian

Sinonasal cancer: AI facilitates breakthrough in diagnostics - Researchers have developed a method for classifying difficult-to-diagnose nasal cavity tumors

Beetroot peptide as potential drug candidate for treating neurodegenerative and inflammatory diseases - Peptide is able to inhibit a particular enzyme that is responsible for the breakdown of messenger molecules in the body

Collective intelligence can help reduce medical misdiagnoses - A fully automated solution significantly increases diagnostic accuracy
Autism, schizophrenia and bipolar disorder may share common underlying factors, study suggests

TakeOne® | Sampling systems | Sartorius
BASF plans significant investment in ibuprofen capacities in Germany and North America - New world-scale ibuprofen production plant in Ludwigshafen
